You have read all your free articles, to continue reading subscribe to read the rest of this content.
Cantargia has submitted the first application to start a phase I/IIa clinical trial with the antibody CAN04 in patients, primarily with non-small cell lung cancer or pancreatic cancer. The trial is planned to be performed at several centres in the BeNeLux and Scandinavia. The goal is to start recAlready a…
Ultimovacs has announced data showing that the company’s universal cancer vaccine UV1 in combination with ipilimumab induces dynamic, multi-functional T cell responses in patients with melanoma, with the potential for protection of 5 years or more. The data will be presented as a poster at the Already a subscriber Login…
Positive results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus standard-of-care abirateroneAlready a subscriber Login You have read all your free articles, to continue reading subscribe to…
Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has giveAlready a subscriber Login You…
